scholarly article | Q13442814 |
P50 | author | Anne-Lise Børresen-Dale | Q11958220 |
Alison Dunning | Q30506457 | ||
Graham Giles | Q30524411 | ||
Diether Lambrechts | Q26923514 | ||
Hoda Anton-Culver | Q28052887 | ||
Montserrat García-Closas | Q28356305 | ||
Gianluca Severi | Q28360445 | ||
Kamila Czene | Q28484009 | ||
Angela Cox | Q28484012 | ||
Barbara Burwinkel | Q28484015 | ||
Heli Nevanlinna | Q29840669 | ||
Simon S. Cross | Q30505778 | ||
Esther M. John | Q59752419 | ||
Douglas F. Easton | Q59812154 | ||
Paul D P Pharoah | Q61822938 | ||
Per Hall | Q62593354 | ||
Peter Devilee | Q37361664 | ||
Taru A. Muranen | Q37371838 | ||
Jingmei Li | Q37371985 | ||
Marjanka K Schmidt | Q37372106 | ||
Grethe Grenaker Alnæs | Q40177166 | ||
Kelly-Anne Phillips | Q41368487 | ||
Børge G. Nordestgaard | Q43530123 | ||
Melissa C. Southey | Q55446228 | ||
John Hopper | Q56726496 | ||
Argyrios Ziogas | Q30831638 | ||
Veli-Matti Kosma | Q37068464 | ||
Vesa Kataja | Q37069167 | ||
Arto Mannermaa | Q37070123 | ||
Caroline Seynaeve | Q37342673 | ||
Thilo Dörk | Q37342847 | ||
Vessela Kristensen | Q37344701 | ||
Marie-Rose Christiaens | Q87946225 | ||
Mark Sherman | Q88087477 | ||
Frederik Marmé | Q88268377 | ||
Laura J Van't Veer | Q92380286 | ||
Maren Weischer | Q96185909 | ||
Manjeet K Bolla | Q114270702 | ||
Mitul Shah | Q114292631 | ||
Mieke Kriege | Q114292663 | ||
Karin Leunen | Q114337516 | ||
Richard R van Hien | Q114337683 | ||
Fergus J. Couch | Q63018779 | ||
Peter A. Fasching | Q64005064 | ||
Arif B. Ekici | Q64409983 | ||
Annika Lindblom | Q64516098 | ||
Irene L Andrulis | Q64516140 | ||
Jianjun Liu | Q68692572 | ||
Jonine Figueroa | Q71778357 | ||
Sara Margolin | Q72940025 | ||
Matthias W. Beckmann | Q72940290 | ||
Stig Egil Bojesen | Q72992763 | ||
Carl Blomqvist | Q73625505 | ||
Annegien Broeks | Q73632596 | ||
Gord Glendon | Q73633107 | ||
Xianshu Wang | Q73864709 | ||
Laura Baglietto | Q74010954 | ||
Henrik Flyger | Q74012148 | ||
Malcolm W. R. Reed | Q74013381 | ||
Maartje J. Hooning | Q74014444 | ||
Natalia V. Bogdanova | Q74171899 | ||
Rob Tollenaar | Q77085802 | ||
Julia A. Knight | Q78316584 | ||
Janet E. Olson | Q78318964 | ||
P2093 | author name string | Qin Wang | |
Alexander Miron | |||
Andreas Meyer | |||
Christof Sohn | |||
Johanna Margriet Collée | |||
P2860 | cites work | ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?* | Q22066036 |
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations | Q28215462 | ||
The CHEK2 gene and inherited breast cancer susceptibility | Q28265315 | ||
Chk1 and Chk2 kinases in checkpoint control and cancer | Q29617706 | ||
Prognosis of Patients With Breast Cancer: Causes of Death and Effects of Time Since Diagnosis, Age, and Tumor Characteristics | Q57568345 | ||
Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying theCHEK2*1100delCGermline Mutation | Q61970254 | ||
Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy | Q40249058 | ||
Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers | Q48002614 | ||
CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. | Q51392341 | ||
The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype | Q33904762 | ||
CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies | Q33910280 | ||
Mendelian randomization: prospects, potentials, and limitations | Q34312296 | ||
CHEK2 is a multiorgan cancer susceptibility gene | Q34551970 | ||
Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence | Q35043093 | ||
Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant | Q35443960 | ||
Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study | Q35794366 | ||
CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls | Q37048943 | ||
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer | Q37218535 | ||
Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? | Q37225727 | ||
Increased risk of breast cancer associated with CHEK2*1100delC | Q80035778 | ||
P433 | issue | 35 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | breast cancer | Q128581 |
heterozygosity | Q124059385 | ||
P304 | page(s) | 4308-4316 | |
P577 | publication date | 2012-10-29 | |
P1433 | published in | Journal of Clinical Oncology | Q400292 |
P1476 | title | CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer | |
P478 | volume | 30 |
Q34042627 | AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014. |
Q39437211 | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers |
Q37329388 | Association of CHEK2 polymorphisms with the efficacy of platinum-based chemotherapy for advanced non-small-cell lung cancer in Chinese never-smoking women |
Q38776757 | Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study |
Q90327632 | Association of a Pathway-Specific Genetic Risk Score With Risk of Radiation-Associated Contralateral Breast Cancer |
Q91879496 | Bilateral Paget's Disease of the Breast in a Patient with CHEK2 Mutation |
Q35000798 | Biology of breast cancer in young women |
Q35054455 | Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network |
Q57420847 | Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study |
Q35180940 | Breast Cancer Update 2014 - Focus on the Patient and the Tumour |
Q39161921 | Breast cancer in young women: an overview |
Q34560743 | CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer |
Q87561146 | Cancer genetic testing panels for inherited cancer susceptibility: the clinical experience of a large adult genetics practice |
Q54108246 | Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients. |
Q47095699 | Clinical and genetic characterization of hereditary breast cancer in a Chinese population |
Q92630618 | Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer Who Are Genetic Carriers, Have a Strong Family History or Are just Young at Presentation |
Q31118195 | Contralateral Prophylactic Mastectomy (CPM) Consensus Statement from the American Society of Breast Surgeons: Data on CPM Outcomes and Risks |
Q26744320 | Contralateral prophylactic mastectomy: current perspectives |
Q33911135 | Counselling framework for moderate-penetrance cancer-susceptibility mutations |
Q33646842 | Estrogen signaling and the DNA damage response in hormone dependent breast cancers |
Q37394076 | FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome |
Q36915151 | Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer |
Q51764547 | Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. |
Q36175072 | Gene-panel sequencing and the prediction of breast-cancer risk |
Q37739048 | Genetic modifiers of CHEK2*1100delC-associated breast cancer risk |
Q64040390 | Genome-wide association study of germline variants and breast cancer-specific mortality |
Q38780469 | Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma |
Q91525724 | Germline variants in cancer genes in high-risk non-BRCA patients from Puerto Rico |
Q38925408 | Hereditary breast and ovarian cancer: new genes in confined pathways |
Q38266306 | Hereditary breast cancer syndromes and genetic testing |
Q93019605 | High risk of breast cancer in women with biallelic pathogenic variants in CHEK2 |
Q40928974 | Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients |
Q36272742 | Inbreeding and homozygosity in breast cancer survival |
Q37378034 | Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model |
Q34996647 | Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer |
Q34983596 | Inherited predisposition to breast cancer among African American women |
Q33618262 | Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients |
Q38184454 | Next-generation sequencing for inherited breast cancer risk: counseling through the complexity |
Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
Q39160490 | Outcomes of retesting BRCA negative patients using multigene panels. |
Q99408631 | Pathogenic Variants in CHEK2 Are Associated With an Adverse Prognosis in Symptomatic Early-Onset Breast Cancer |
Q37307937 | Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium |
Q37131918 | Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families |
Q41011976 | Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods |
Q92055460 | Prediction and clinical utility of a contralateral breast cancer risk model |
Q87933309 | Rapid and cost effective screening of breast and ovarian cancer genes using novel sequence capture method in clinical samples |
Q92710828 | Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients |
Q35977371 | Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers |
Q34113473 | Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy |
Q54375866 | Survival from breast cancer in patients with CHEK2 mutations. |
Q38979257 | Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care |
Q98293212 | Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer |
Q52632717 | Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers. |
Search more.